Seeing Beyond the Symptoms: Early Diagnosis and Treatment of Dry Eye and Meibomian Gland Dysfunction

Seeing Beyond the Symptoms: Early Diagnosis and Treatment of Dry Eye and Meibomian Gland Dysfunction

Seeing Beyond the Symptoms: Early Diagnosis and Treatment of Dry Eye and Meibomian Gland Dysfunction
RestartResume

tbd

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dry eye disease is one of the most common ophthalmic complaints; it results from the activity of various pathways and is considered a multifactorial disease. An important factor that contributes to the onset of dry eye disease is meibomian gland dysfunction. Meibomian gland dysfunction causes a disruption in the tear film lipid layer, which affects the rate of tear evaporation. This evaporation leads to tear hyperosmolarity, eventually triggering the onset of dry eye disease. Dry eye disease and meibomian gland dysfunction are strongly associated with each other, such that many of their risk factors, signs, and symptoms overlap. In this educational podcast, our expert faculty will review the association between dry eye disease and meibomian gland dysfunction, and highlight best practices for assessment, diagnosis, and management.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

    Disclosure of relevant financial relationships are as follows:

    Paul P. Doghramji, MD
    Advisory Board/Consultant: Eisai; Idorsia Pharmaceuticals, Ltd; Jazz Pharmaceuticals
    Shareholder: Pfizer
    Speaker’s Bureau: AbbVie, Inc; Eisai; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals; Merck & Co. 

    Eric D. Donnenfeld, MD
    Advisory Board/Consultant: Aeon; Alcon; Allegro; Allergan, plc; Bausch & Lomb, Inc; BlephEx; BVI Medical; CorneaGen; CRST; Dompé farmaceutici S.p.A; Foresight; Glaukos Corp; Johnson & Johnson; Kala Pharmaceuticals, Inc; Katena Products, Inc; Lacripen; Mimetogen Pharmaceuticals; Nanowafer Inc; NovaBay Pharmaceuticals, Inc; Novartis; Novaliq; Oculis; Oyster Point Pharmaceutical; Pfizer; Omeros Corporation; PRN Pharmacal; Regener-Eyes; ReTear, Inc; ReSearch Pharmaceutical Services; Shire; Strathspey Crown; Sun Pharmaceutical Industries Ltd; Surface Pharmaceuticals; TearLab; TearScience; Thea Pharma Inc

    Shareholder: Aeon; Avedro, Inc; CorneaGen; Lacripen; Mimetogen Pharmaceuticals; NovaBay Pharmaceuticals, Inc; Oculis; Regener-Eyes; ReTear, Inc; ReSearch Pharmaceutical Services; Strathspey Crown; Surface Pharmaceuticals; TearLab

    Independent Clinical Reviewer
    Dominick Opitz, OD:
    Advisory Board/Consultant: Dompe Pharmaceuticals; Bausch & Lomb*; Shire*
    Speaker’s Bureau: Bausch & Lomb* 

    *Relationship has ended

    Planning Committee
    John JD Juchniewicz, MCIS, CHCP, FACEHP, American Academy of CME: No relevant financial relationships with ineligible companies to disclose.

    Kimberly Miniter, M.Ed., Mary Simmons, Chris Washburn, PhD: No relevant financial relationships with ineligible companies to disclose.

  • Target Audience

    The primary target audience for this educational initiative consists of ophthalmologists and optometrists. A secondary audience will consist of primary care providers and will include physicians, nurse practitioners, and physician assistants.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • DEVELOP a clinical protocol for diagnosing and managing dry eye disease (DED) and meibomian gland dysfunction (MGD) in daily patient care
    • SELECT the appropriate diagnostic tests to identify symptomatic and asymptomatic patients with early DED and MGD
    • OUTLINE the available pharmacologic and nonpharmacologic therapies for the management of patients with DED and MGD
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc and Spire Learning. American Academy of CME, Inc is jointly accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for the health care team.

    American Academy of CME, Inc designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of CME, Inc designates this live activity for a maximum of 0.5 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity. If you are an optometrist specialist seeking COPE credit, please send an inquiry to info@reachmd.com

  • Disclaimer

    The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Spire Learning. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This educational activity is jointly provided by American Academy of CME, Inc and Spire Learning.

  • Commercial Support

    This activity is supported by an independent medical education grant from Alcon Vision, LLC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free